Other Health News Topics Other STDs Herpes
ASM Microbe 2016: Novel Immune Therapy GEN-003 Improves Genital Herpes
- Details
- Category: Herpes
- Published on Thursday, 23 June 2016 00:00
- Written by Liz Highleyman
GEN-003, a therapeutic vaccine containing recombinant herpes simplex virus (HSV) antigens, showed significant antiviral activity lasting up to a year and reduced the number of genital herpes lesions and days with recurrences, researchers reported this week at the ASM Microbe 2016 meeting in Boston.
HIVR4P 2014: Vaginal Rings Show Promise for HIV Prevention
- Details
- Category: Microbicides
- Published on Tuesday, 04 November 2014 00:00
- Written by Liz Highleyman
A silicone intravaginal ring that releases the antiretroviral drugs dapivirine and darunavir was shown to reach levels expected to be effective in vaginal and cervical fluid and tissues in monkeys, researchers reported at the HIV Research for Prevention meeting last week in Cape Town. A related study found that a single ring can potentially serve multiple purposes, preventing HIV, genital herpes, HPV, and pregnancy.
Researchers Report Setbacks on Herpes Simplex Vaccine and Treatment
- Details
- Category: Herpes
- Published on Friday, 24 February 2012 00:00
- Written by Liz Highleyman
An experimental herpes simplex virus (HSV) vaccine partially protected women against infection with HSV type 1 but not type 2, according to a recent report in the New England Journal of Medicine. Another recent study found that antiviral treatment with acyclovir (Zovirax) or valacyclovir (Valtrex) did not prevent periodic HSV-2 reactivation and viral shedding.
HIVR4P 2014: Tenofovir Gel Associated with Lower Herpes Simplex Risk for Women
- Details
- Category: Microbicides
- Published on Friday, 31 October 2014 00:00
- Written by Lesley Odendal
The risk of acquiring herpes simplex virus type 2 (HSV-2) was reduced by 46% among women who regularly used a vaginal gel containing tenofovir, according to a secondary analysis of the VOICE trial presented at the HIV Research for Prevention conference (R4P) this week in Cape Town. There was no significant difference in the age, marital status, country, practice of anal sex, HIV status, or hormonal contraceptive use between women who acquired HSV-2 and those who did not.
Tenofovir Microbicide Gel May Prevent Genital Herpes in Addition to HIV Infection
- Details
- Category: Microbicides
- Published on Tuesday, 25 October 2011 00:00
- Written by NIH
A vaginal gel containing the HIV nucleotide reverse transcriptase inhibitor tenofovir (known as Viread in pill form, also in the Truvada and Atripla coformulations) inhibits replication of herpes simplex virus, researchers reported in the October 4, 2011, issue of Cell Host and Microbes. Tenofovir gel has already been shown to reduce HIV infection by about 40%, and the new findings suggest it may have a dual benefit.
HIVR4P 2014: Model Suggests More Frequent Truvada PrEP Needed for Vaginal vs Anal Sex
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Friday, 31 October 2014 00:00
- Written by Liz Highleyman
Tenofovir reaches lower levels in vaginal and cervical tissue compared with rectal tissue, helping to explain why pre-exposure prophylaxis (PrEP) did not protect women as much as gay and bisexual men in clinical trials, and suggesting that women having vaginal sex may need to take PrEP more often than people having anal sex, researchers reported at the HIV Research for Prevention meeting this week in Cape Town.
IAS 2011: Anti-Herpes Drugs Reduce HIV Viral Load, Slow Disease Progression
- Details
- Category: HIV Disease Progression
- Published on Tuesday, 02 August 2011 00:00
- Written by Liz Highleyman
Several studies presented at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) last month in Rome showed that treating herpes simplex virus type 2 (HSV-2) with acyclovir or valacyclovir (Valtrex) reduced HIV viral load and slowed disease progression.
Helicase Inhibitor Pritelivir Shows Promise Against Genital Herpes
- Details
- Category: Herpes
- Published on Friday, 31 January 2014 00:00
- Written by Liz Highleyman
Pritelivir, a helicase inhibitor that interferes with viral replication, reduced the rate of herpes simplex virus type 2 (HSV-2) genital shedding, which has the potential to reduce sexual transmission, according to a small study described in the January 16, 2014, New England Journal of Medicine.
Genital Herpes Virus Can Spread Despite Lack of Symptoms
- Details
- Category: Herpes
- Published on Saturday, 23 April 2011 05:17
- Written by Liz Highleyman
People without genital sores or other symptoms can still shed and transmit herpes simplex virus type 2 (HSV-2) during sex, according to a recent U.S. study. 
Herpes Simplex and Cytomegalovirus Linked to Cognitive Impairment
- Details
- Category: Other Health News
- Published on Wednesday, 18 December 2013 00:00
- Written by University of Michigan
Latent herpes simplex virus (HSV) or cytomegalovirus (CMV) infection may contribute to impaired cognitive processing for people of all age groups, possibly due to resulting inflammation, according to study results published in the November 18, 2013, advance edition of the Journal of Infectious Diseases.
Oral Tenofovir Does Not Reduce Herpes Virus Shedding
- Details
- Category: Herpes
- Published on Tuesday, 25 January 2011 12:55
- Written by Liz Highleyman
HIV positive people who took tenofovir (Viread, also in the Truvada and Atripla combination pills) as part of their antiretroviral regimen were no less likely to shed herpes simplex virus 1 or 2 (HSV-1 or HSV-2) than individuals using non-tenofovir regimens, according to research described in the January 14, 2011, issue of AIDS. These findings are notable because a recent microbicide study found that a tenofovir gel reduced the likelihood of HSV-2 infection.
ICAAC 2013: Novel Therapeutic Vaccine Reduces Genital Herpes Shedding
- Details
- Category: Herpes
- Published on Tuesday, 17 September 2013 00:00
- Written by Genocea Biosciences
An experimental immune-modulating vaccine significantly reduced shedding of herpes simplex virus type 2 (HSV-2) in people with recurrent genital herpes, according to a late-breaker presentation at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) this week in Denver. The vaccine appeared safe and well-tolerated.
Web Design and Development by